Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Aug;3(4):245-56.
doi: 10.1016/s1479-666x(05)80086-1.

Adjuvant therapies in the treatment of stage II and III malignant melanoma

D Kavanagh  1 , A D K Hill, B Djikstra, R Kennelly, E M W McDermott, N J O'Higgins
Affiliations
Review

Adjuvant therapies in the treatment of stage II and III malignant melanoma

D Kavanagh et al. Surgeon. 2005 Aug.

Abstract

Background: The incidence of cutaneous melanoma has increased during the past three decades. The development of sentinel lymph node biopsy has facilitated better staging. Despite these improvements, 5-year survival rates for American Joint Committee on Cancer stage II and III disease range from 50%-90%.

Methods: A review of the current literature concerning adjuvant therapies in patients with stage II and III malignant melanomas was undertaken.

Results: The focus of adjuvant therapies has shifted from radiotherapy, BCG and levamisole to newer biological agents. Interferon, interleukin and vaccines have been evaluated but none of these agents have demonstrated an increase in overall survival in patients with stage II and III melanoma. Interferon can prolong disease-free interval.

Conclusion: At present, no adjuvant therapy improves overall survival in patients with stage II and III melanoma. New staging allows more accurate stratification of patients for clinical trials.

PubMed Disclaimer

LinkOut - more resources